Jon Glass, MD

Jon Glass, MD

Contact Dr.  Glass

901 Walnut Street
Suite 400
Philadelphia, PA 19107

(215) 955-7000
(215) 503-9170 fax

Most Recent Peer-reviewed Publications

  1. Rapid Early Tumor Progression is Prognostic in Glioblastoma Patients
  2. Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas
  3. Bevacizumab in recurrent glioblastoma
  4. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
  5. Correction to: Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment (Journal of Neuro-Oncology, (2018), 137, 1, (171-177), 10.1007/s11060-017-2709-0)
  6. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment
  7. Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma
  8. Current management of primary central nervous system lymphoma
  9. Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era a correlative analysis based on nrg oncology RTOG 0525
  10. Reply to M.C. Chamberlain
  11. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227
  12. Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas
  13. Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better
  14. Primary central nervous system Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly: a clinicopathologic study of five cases
  15. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme
  16. A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma
  17. A phase i study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas
  18. A 60-year-old indian male with altered sensorium and extensive lymphoma of the scalp
  19. Improving prognosis of glioblastoma in the 21st century: Who has benefited most?
  20. Characterization and outcomes of optic nerve gliomas: A population-based analysis